SecBot SecBot

PHAR

Pharming Group N.V.
Nasdaq· Pharmaceutical Preparations· Inc. P7· CIK 0001828316 Biotech & Drug Discovery
$12.59 −0.01 (−0.08%)
Nov 16 4:00 PM ET · prev $12.60
Market cap
$907.5M
Small cap
Consensus
Buy
93% Buy or better · 14 analysts
Median target
$38.00
+202% · range $25.80–41.00
1 year
−22.4%
from $16.23 · Nov 17
30 days
+38.2%
from $9.11
52-week range
$9.11–21.18
−41% from high · low Oct 19
Avg volume 20D
17.1K
Oct 26 spike 43.4K
Short interest
25.8K
≈0.0% of shares · +92.0%
Days to cover
1.4
at average volume
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 12 reports · 90 days
Balance 2 bearish · 10 bullish oldest → newest, height = score
Avg score ·High conf. 12/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q3 2026: 1 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    13 of 14 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.107 → $0.060 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersBUILDING

    Short interest +92.0% to 25.8K shares. 1.4 days to cover, ≈0.0% of shares.

  • TrendUPTREND

    15% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BNP PARIBAS FINANCIAL MARKETSDOUBLED8,705$87.0K
BNP PARIBAS FINANCIAL MARKETSTRIM300$4.2K
NewEdge Advisors, LLCNEAR_EXIT187$2.6K
OSAIC HOLDINGS, INC.NEAR_EXIT16$222.00
MORGAN STANLEYADD11,489$191.2K
NewEdge Advisors, LLCNEAR_EXIT2,150$35.8K
BNP PARIBAS FINANCIAL MARKETSTRIM400$6.7K
NewEdge Advisors, LLCDOUBLED28,868$510.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 93% rate it Buy or better
Strong Buy7Buy6Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +202%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 29, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Sep 22, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 14, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 3, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy

Earnings setup

Estimates
$0.06
EPS estimate, this quarter
−44%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.06$0.02–$0.10-77.8%$107.5M
Next Q-$0.01-$0.01–-$0.01No data$77.0M
Current FY$0.26$0.04–$0.48-43.5%$387.3M
Next FY$0.18$0.04–$0.32-41.4%$422.0M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

Short side

FINRA· Oct 30, 2026
25,783
shares short
+92.0%
vs prior settlement
1.4
days to cover
≈0.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.

SecBot reports

15 filings · 3 press releases · 12 bullish · 1 bearish · 2 neutral
All PHAR filing & press-release reports (18)